NOVEL ENZYME IMMOBILIZATION FOR BIOSENSOR APPLICATIONS

Information

  • Research Project
  • 3498645
  • ApplicationId
    3498645
  • Core Project Number
    R43GM046164
  • Full Project Number
    1R43GM046164-01
  • Serial Number
    46164
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1991 - 33 years ago
  • Project End Date
    8/31/1991 - 32 years ago
  • Program Officer Name
  • Budget Start Date
    3/1/1991 - 33 years ago
  • Budget End Date
    8/31/1991 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/27/1991 - 33 years ago

NOVEL ENZYME IMMOBILIZATION FOR BIOSENSOR APPLICATIONS

DESCRIPTION (Adapted from applicant's abstract): Enzyme crystals, cross-linked using a bifunctional reagent such as glutaraldehyde, constitute a novel form of enzyme immobilization. Such cross-linked immobilized enzyme crystals (CLIECs) are superior to conventionally immobilized enzymes in many respects. For example, the crystal lattice interactions, supplemented by chemical cross-links, provide the individual enzyme molecules within a CLIEC with an enhanced stability that allows for function in harsh environments (such as elevated temperatures and unusual solvents) that would not otherwise be compatible with catalytic activity. These features of CLIECs lend themselves to biosensor applications, where it is desirable to produce the largest possible signal from the smallest possible volume of catalyst and quantity of substrate. In the Phase I study, CLIECs of bacterial luciferase from "Vibrio harveyi" will be investigated in a prototype system to demonstrate the feasibility of this approach to biosensor applications. Luciferase is chosen because it produces light as consequence of its catalytic activity. The exceptional sensitivity and efficiency of photon sensing devices can be exploited to detect femtomolar concentrations of selected analytes under appropriate experimental conditions. A broad array of clinically interesting enzymatic reactions have been described in the literature that can be readily coupled to light production by a luciferase CLIEC.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    VERTEX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES